Publish your oncology research
Our high-impact oncology journals disseminate cutting-edge data to physicians, medical researchers, and healthcare professionals around the world supporting revolutionary treatments and research advances.
We work with all of the top 10 largest drug companies ranked by Forbes¹ and 86% of the top 50 global pharma companies ranked by Pharmaceutical Executive.²
Our oncology portfolio in the fields of immunology and hematology champions the most relevant, up-to-date, and scientifically sound research on topics such as:
- Cancer immunology and immunotherapies
- Common and rare blood diseases
- Drug development and research (including orphan drugs)
- Inflammation in cancer
Like you, we value high visibility and timely publication. To extend your research impact, publish open access and use our Accelerated Publication service, which fast-tracks your article from submission to online publication in as little as three weeks. Help your article reach non-specialist audiences by publishing a Plain Language Summary (PLS).
Interested in publishing with us?
Our editorial team is happy to speak with you about the best options for your paper.
Explore the oncology portfolio
Learn more about the featured journals below, then browse by therapy area to find the right fit for your paper.
Leukemia and Lymphoma
An international forum for publication of high-quality clinical, translational, and basic science research, and original observations relating to all aspects of hematological malignancies.
2020 Impact Factor: 3.28‡
Expert Review of Anticancer Therapy†
Expert appraisal and commentary on the major trends in cancer care, highlighting the performance of new therapeutic and diagnostic approaches.
2020 Impact Factor: 4.512‡
Cancer Management and Research*§
International, peer-reviewed, open access journal. Focusing on cancer research and the optimal use of preventative and integrated treatment interventions to achieve improved outcomes, enhanced survival, and quality of life for the cancer patient.
2020 Impact Factor: 3.989‡
OncoImmunology*
High-profile, open access research in fundamental, translational, and clinical areas of tumor immunology.
2020 Impact Factor: 8.11‡
OncoTargets and Therapy*§
High-quality, open access journal focused on the molecular diagnosis of and targeted molecular or precision therapy for all types of cancer.
2020 Impact Factor: 4.147‡
Cancer Biology & Therapy
Timely original research, reviews, and op-ed pieces on the molecular basis of cancer, including articles with translational relevance to diagnosis or therapy.
2020 Impact Factor: 4.742‡
Cancer Investigation
Impact Factor: 2.176‡
OncoImmunology*
Impact Factor: 8.11‡
Journal of Hepatocellular Carcinoma*§
Impact Factor: 5.828‡
Acta Oncologica
Impact Factor: 4.089‡
Cancer Biology & Therapy
Impact Factor: 4.742‡
Expert Review of Anticancer Therapy†
Impact Factor: 4.512‡
OncoTargets and Therapy*§
Impact Factor: 4.147‡
Leukemia and Lymphoma
Impact Factor: 3.28‡
Cancer Management and Research*§
Impact Factor: 3.989‡
Nutrition and Cancer
Impact Factor: 2.9‡
Cancer Investigation†
Impact Factor: 2.176‡
Journal of Chemotherapy
Impact Factor: 1.714‡
Lung Cancer: Targets and Therapy*§
ESCI-indexed
Breast Cancer: Targets and Therapy*§
ESCI-indexed
COPD: Journal of Chonric Obstructive Pulmonary Disease
Impact Factor: 2.409‡
Scandanavian Journal of Gastroenterology
Impact Factor: 2.425‡
Scandanvian Cardiovascular Journal
Impact Factor: 1.589‡
Nanotoxiciology
Impact Factor: 5.913‡
Expert Review of Vaccines†
Impact Factor: 5.217‡
mAbs*
Impact Factor: 5.857‡
Expert Review of Clinical Immunology†
Impact Factor: 4.473‡
Expert Opinion on Biological Therapy†
Impact Factor: 4.388‡
Human Vaccines and Immunotherapeutics
Impact Factor: 3.452‡
Expert Opinion on Orphan Drugs†
Impact Factor: 0.694‡
Journal of Inflammation Research*<§ Impact Factor: 6.922‡
Transplant Research and Risk Management*§
ESCI-indexed
Expert Review of Hematology†
Impact Factor: 2.929‡
Hematology*
Impact Factor: 2.269‡
Pediatric Hematology and Oncology
Impact Factor: 1.969‡
Hemoglobin
Impact Factor: 0.849‡
Journal of Blood Medicine*§
ESCI-indexed
Blood and Lymphatic Cancer: Targets and Therapy*§
ESCI-indexed
*Fully open access journal.
†Offers Accelerated Publication.
‡Copyright: 2019 Journal Citation Reports®, Clarivate Analytics, 2020.
§Published by Dove Medical Press.
Why publish with Taylor & Francis?
Quality
Research articles are assessed by independent peer reviewers for quality, validity, and relevance. Many journals in our medical portfolio are indexed in the Science Citation Index, Science Citation Index Expanded, Scopus, and MEDLINE.
Reach
Taylor & Francis is a leading scholarly publisher. Amazon’s Alexa service ranks Taylor & Francis Online among the world’s most-visited academic journals publishing platforms.
Expertise
Contributors to our medical journals benefit from direct and prompt communication with in-house editorial specialists.
Industry peers
Taylor & Francis publishes research from top pharmaceutical companies like Pfizer, Roche, GlaxoSmithKline, and Sanofi.
Additional services for corporate researchers
Our Commercial Services team can tailor ad placements, reprint packages, and research access options to fit your organization's needs.
Want to learn more?
Complete the online enquiry form on this page for a direct response from a member of our editorial team.